According to Dynavax Technologies 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6.3098. At the end of 2023 the company had a P/S ratio of 7.78.
Year | P/S ratio | Change |
---|---|---|
2023 | 7.78 | 314.15% |
2022 | 1.88 | -51.09% |
2021 | 3.84 | -63.54% |
2020 | 10.5 | -22.67% |
2019 | 13.6 | -80.59% |
2018 | 70.2 | -97.98% |
2017 | > 1000 | 25045.31% |
2016 | 13.8 | -95% |
2015 | 276 | 418.98% |
2014 | 53.2 | 16.11% |
2013 | 45.8 | -14.64% |
2012 | 53.6 | 175.33% |
2011 | 19.5 | 26.1% |
2010 | 15.4 | 708.02% |
2009 | 1.91 | 111.82% |
2008 | 0.9025 | -93.74% |
2007 | 14.4 | -80.83% |
2006 | 75.2 | 1006.01% |
2005 | 6.80 | -46.81% |
2004 | 12.8 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 2.46 | -61.05% | ๐บ๐ธ USA |
Amgen AMGN | 5.14 | -18.59% | ๐บ๐ธ USA |
Biogen BIIB | 3.09 | -50.99% | ๐บ๐ธ USA |
Gilead Sciences GILD | 3.01 | -52.32% | ๐บ๐ธ USA |
Merck MRK | 5.53 | -12.39% | ๐บ๐ธ USA |
AstraZeneca AZN | 5.09 | -19.37% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | 2.22 | -64.78% | ๐ฌ๐ง UK |
Agenus
AGEN | 1.59 | -74.86% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | 0.9871 | -84.36% | ๐ฎ๐ฑ Israel |